CO5611161A2 - Tratar desorden inmunologico usando agonistas de interleucina-21/receptor de interleucina-21 - Google Patents
Tratar desorden inmunologico usando agonistas de interleucina-21/receptor de interleucina-21Info
- Publication number
- CO5611161A2 CO5611161A2 CO05095726A CO05095726A CO5611161A2 CO 5611161 A2 CO5611161 A2 CO 5611161A2 CO 05095726 A CO05095726 A CO 05095726A CO 05095726 A CO05095726 A CO 05095726A CO 5611161 A2 CO5611161 A2 CO 5611161A2
- Authority
- CO
- Colombia
- Prior art keywords
- agonist
- interleucine
- antibody
- polypeptide
- agonists
- Prior art date
Links
- 208000026278 immune system disease Diseases 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 9
- 108010074108 interleukin-21 Proteins 0.000 abstract 9
- 238000000034 method Methods 0.000 abstract 9
- 102100030704 Interleukin-21 Human genes 0.000 abstract 5
- 230000001270 agonistic effect Effects 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 2
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 abstract 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 2
- 229960002930 sirolimus Drugs 0.000 abstract 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 abstract 1
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 abstract 1
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 abstract 1
- 229960000681 leflunomide Drugs 0.000 abstract 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 abstract 1
- 229960000485 methotrexate Drugs 0.000 abstract 1
- 229960000235 temsirolimus Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45692003P | 2003-03-21 | 2003-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5611161A2 true CO5611161A2 (es) | 2006-02-28 |
Family
ID=33098171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO05095726A CO5611161A2 (es) | 2003-03-21 | 2005-09-21 | Tratar desorden inmunologico usando agonistas de interleucina-21/receptor de interleucina-21 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20060159655A1 (https=) |
| EP (1) | EP1608315A4 (https=) |
| JP (1) | JP2006523682A (https=) |
| KR (1) | KR20060015482A (https=) |
| CN (1) | CN1849131A (https=) |
| AU (1) | AU2004224277A1 (https=) |
| BR (1) | BRPI0408523A (https=) |
| CA (1) | CA2518854A1 (https=) |
| CO (1) | CO5611161A2 (https=) |
| CR (1) | CR7994A (https=) |
| EC (1) | ECSP056027A (https=) |
| IL (1) | IL198102A0 (https=) |
| MX (1) | MXPA05010035A (https=) |
| NO (1) | NO20054343L (https=) |
| RU (1) | RU2005132458A (https=) |
| WO (1) | WO2004084835A2 (https=) |
| ZA (1) | ZA200507235B (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057128A (en) | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| CN1688340A (zh) | 2002-07-15 | 2005-10-26 | 韦思公司 | 调节t辅助(th)细胞发育和功能的方法和组合物 |
| CA2518371A1 (en) | 2003-03-14 | 2004-09-30 | Wyeth | Antibodies against human il-21 receptor and uses therefor |
| US7276478B2 (en) * | 2003-09-25 | 2007-10-02 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| US20060228331A1 (en) | 2003-10-10 | 2006-10-12 | Novo Nordisk A/S | IL-21 Derivatives and variants |
| US20060024268A1 (en) * | 2004-05-19 | 2006-02-02 | Wyeth | Modulation of immunoglobulin production and atopic disorders |
| CA2574848A1 (en) * | 2004-08-05 | 2006-12-21 | Wyeth | Antagonizing interleukin-21 receptor activity |
| GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis | |
| AU2006237329B2 (en) * | 2005-04-18 | 2012-04-12 | Novo Nordisk A/S | IL-21 variants |
| AU2006340750B2 (en) | 2005-11-28 | 2013-03-07 | Zymogenetics, Inc. | IL-21 antagonists |
| AU2006341398B9 (en) * | 2005-11-28 | 2012-02-02 | Zymogenetics, Inc. | IL-21 receptor antagonists |
| EP3103813A1 (en) * | 2007-12-07 | 2016-12-14 | ZymoGenetics, Inc. | Anti-human il-21 monoclonal antibodies |
| WO2009100035A2 (en) * | 2008-02-01 | 2009-08-13 | Wyeth | Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3) |
| EP2296689A1 (en) * | 2008-05-23 | 2011-03-23 | Wyeth LLC | Methods of treatment utilizing binding proteins of the interleukin-21 receptor |
| AR071885A1 (es) | 2008-05-23 | 2010-07-21 | Wyeth Corp | Proteinas de union al receptor de interleuquina 21 |
| JP2012504939A (ja) * | 2008-09-23 | 2012-03-01 | ワイス・エルエルシー | 架橋結合タンパク質による活性化シグナルの産生を予測するための方法 |
| DK2344677T3 (en) | 2008-10-08 | 2017-07-24 | Cambridge Entpr Ltd | METHODS AND COMPOSITIONS FOR DIAGNOSTICATION AND TREATMENT OF AUTOIMMUNIC DISEASE SECONDARY TO MULTIPLE SCLEROSIS |
| AU2011258165B2 (en) * | 2010-05-26 | 2016-11-17 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
| HRP20200470T1 (hr) | 2011-01-18 | 2020-10-02 | Bioniz, Llc | Pripravci za modulaciju aktivnosti gama-c-citokina |
| JP6133790B2 (ja) * | 2011-02-18 | 2017-05-24 | ザ スクリプス リサーチ インスティテュート | ミエリン形成細胞運命へのオリゴデンドロサイト前駆細胞の定方向分化 |
| US9959384B2 (en) | 2013-12-10 | 2018-05-01 | Bioniz, Llc | Methods of developing selective peptide antagonists |
| CN119684428A (zh) | 2015-10-09 | 2025-03-25 | 比奥尼斯治疗公司 | 调节γC-细胞因子活性 |
| SG11201803330WA (en) | 2015-10-22 | 2018-05-30 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| WO2018187499A1 (en) | 2017-04-07 | 2018-10-11 | Bioniz, Llc | Stable modulators of gamma-c-cytokine activity |
| KR102454376B1 (ko) * | 2018-07-04 | 2022-10-17 | 서울대학교산학협력단 | 신경손상의 면역세포치료 |
| US11518792B2 (en) | 2018-08-30 | 2022-12-06 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and uses thereof |
| CA3109361A1 (en) | 2018-08-30 | 2020-03-05 | HCW Biologics, Inc. | Single-chain and multi-chain chimeric polypeptides and uses thereof |
| US11401324B2 (en) | 2018-08-30 | 2022-08-02 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| EP3976182A4 (en) | 2019-05-03 | 2023-01-18 | Bioniz, LLC | MODULATION OF THE EFFECTS OF GAMMA CYTOKINE SIGNALING FOR THE TREATMENT OF ALOPECIA AND ALOPECIA-ASSOCIATED DISORDERS |
| CN120924491A (zh) | 2019-06-21 | 2025-11-11 | 免疫生物公司 | 多链嵌合多肽和其用途 |
| CA3169243A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| AU2021220870A1 (en) | 2020-02-11 | 2022-08-04 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| WO2021163299A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Chromatography resin and uses thereof |
| CN115836087A (zh) | 2020-04-29 | 2023-03-21 | Hcw生物科技公司 | 抗cd26蛋白及其用途 |
| KR20230035239A (ko) * | 2020-05-08 | 2023-03-13 | 앨러스틴 스킨케어, 인크. | 염증 및 상처 치유를 조절하기 위한 조성물 및 방법 |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| JP2023527869A (ja) | 2020-06-01 | 2023-06-30 | エイチシーダブリュー バイオロジックス インコーポレイテッド | 加齢関連障害の治療法 |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| WO2022117569A1 (en) | 2020-12-02 | 2022-06-09 | Oncurious Nv | A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer |
| WO2023201311A1 (en) | 2022-04-13 | 2023-10-19 | HCW Biologics, Inc. | Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder |
| EP4646225A1 (en) * | 2023-01-06 | 2025-11-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010025022A1 (en) * | 1997-11-26 | 2001-09-27 | Kikly Kristine Kay | Hnovilr |
| US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| US7189400B2 (en) * | 1998-03-17 | 2007-03-13 | Genetics Institute, Llc | Methods of treatment with antagonists of MU-1 |
| CA2329274A1 (en) * | 1998-05-29 | 1999-12-02 | Steven M. Ruben | Interleukin-21 |
| WO2000008152A1 (en) * | 1998-08-04 | 2000-02-17 | Regeneron Pharmaceuticals, Inc. | Novel orphan cytokine receptors |
| US6576744B1 (en) * | 1998-09-23 | 2003-06-10 | Zymogenetics, Inc. | Cytokine receptor zalpha11 |
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| US20020090680A1 (en) * | 1999-05-18 | 2002-07-11 | Millennium Pharmaceuticals, Inc. | Novel IL-9/IL-2 receptor-like molecules and uses thereof |
| ES2279809T3 (es) * | 2000-04-05 | 2007-09-01 | Zymogenetics, Inc. | Receptores de citoquina zalfa11 solubles. |
| ES2629395T3 (es) * | 2001-10-04 | 2017-08-09 | Genetics Institute, Llc | Métodos y composiciones para modular la actividad de la interleucina-21 |
| DK1451322T3 (da) * | 2001-11-05 | 2010-02-01 | Zymogenetics Inc | Il-21-antagonister |
| CA2481304A1 (en) * | 2002-03-27 | 2003-10-09 | Patrick Hwu | Method for treating cancer in humans |
| US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
| MXPA04012116A (es) * | 2002-06-07 | 2005-04-19 | Zymogenetics Inc | Uso del il-21 en cancer y otras aplicaciones terapeuticas. |
| CN1688340A (zh) * | 2002-07-15 | 2005-10-26 | 韦思公司 | 调节t辅助(th)细胞发育和功能的方法和组合物 |
| CA2518371A1 (en) * | 2003-03-14 | 2004-09-30 | Wyeth | Antibodies against human il-21 receptor and uses therefor |
| US20060024268A1 (en) * | 2004-05-19 | 2006-02-02 | Wyeth | Modulation of immunoglobulin production and atopic disorders |
| CA2574848A1 (en) * | 2004-08-05 | 2006-12-21 | Wyeth | Antagonizing interleukin-21 receptor activity |
| US7533965B2 (en) * | 2005-03-07 | 2009-05-19 | Eastman Kodak Company | Apparatus and method for electrostatically charging fluid drops |
| GT200600148A (es) * | 2005-04-14 | 2006-11-22 | Metodos para el tratamiento y la prevencion de fibrosis |
-
2004
- 2004-03-22 KR KR1020057017652A patent/KR20060015482A/ko not_active Withdrawn
- 2004-03-22 BR BRPI0408523-0A patent/BRPI0408523A/pt not_active IP Right Cessation
- 2004-03-22 EP EP04758055A patent/EP1608315A4/en not_active Withdrawn
- 2004-03-22 ZA ZA200507235A patent/ZA200507235B/en unknown
- 2004-03-22 CA CA002518854A patent/CA2518854A1/en not_active Abandoned
- 2004-03-22 MX MXPA05010035A patent/MXPA05010035A/es unknown
- 2004-03-22 RU RU2005132458/13A patent/RU2005132458A/ru unknown
- 2004-03-22 WO PCT/US2004/008833 patent/WO2004084835A2/en not_active Ceased
- 2004-03-22 JP JP2006507478A patent/JP2006523682A/ja active Pending
- 2004-03-22 US US10/806,611 patent/US20060159655A1/en not_active Abandoned
- 2004-03-22 AU AU2004224277A patent/AU2004224277A1/en not_active Abandoned
- 2004-03-22 CN CNA2004800076306A patent/CN1849131A/zh active Pending
-
2005
- 2005-09-16 CR CR7994A patent/CR7994A/es not_active Application Discontinuation
- 2005-09-20 EC EC2005006027A patent/ECSP056027A/es unknown
- 2005-09-20 NO NO20054343A patent/NO20054343L/no not_active Application Discontinuation
- 2005-09-21 CO CO05095726A patent/CO5611161A2/es unknown
-
2009
- 2009-04-07 IL IL198102A patent/IL198102A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20060159655A1 (en) | 2006-07-20 |
| ECSP056027A (es) | 2006-09-18 |
| AU2004224277A1 (en) | 2004-10-07 |
| JP2006523682A (ja) | 2006-10-19 |
| KR20060015482A (ko) | 2006-02-17 |
| CR7994A (es) | 2006-10-17 |
| WO2004084835A3 (en) | 2006-05-26 |
| ZA200507235B (en) | 2007-03-28 |
| IL198102A0 (en) | 2009-12-24 |
| NO20054343L (no) | 2005-11-24 |
| NO20054343D0 (no) | 2005-09-20 |
| WO2004084835A2 (en) | 2004-10-07 |
| BRPI0408523A (pt) | 2006-03-21 |
| MXPA05010035A (es) | 2005-11-17 |
| CN1849131A (zh) | 2006-10-18 |
| EP1608315A2 (en) | 2005-12-28 |
| RU2005132458A (ru) | 2006-03-20 |
| CA2518854A1 (en) | 2004-10-07 |
| EP1608315A4 (en) | 2008-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5611161A2 (es) | Tratar desorden inmunologico usando agonistas de interleucina-21/receptor de interleucina-21 | |
| JP7288920B2 (ja) | シンデカン－２のモジュレーターとその使用 | |
| EP2056838B1 (en) | Combination therapy for treatment of immune disorders | |
| Okiyama et al. | Therapeutic effects of interleukin‐6 blockade in a murine model of polymyositis that does not require interleukin‐17A | |
| RU2192281C2 (ru) | Способы и композиции для иммуномодуляции | |
| RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
| JP2006523682A5 (https=) | ||
| RU2015114923A (ru) | СПОСОБЫ ЛЕЧЕНИЯ IL-1β-ЗАВИСИМЫХ ЗАБОЛЕВАНИЙ | |
| US20110002928A1 (en) | Uses of Mammalian Cytokine; Related Reagents | |
| WO2004071517A2 (en) | Uses of il-23 related reagents | |
| ATE283289T1 (de) | Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten | |
| HRP20110334T1 (hr) | PROTUTIJELA SPECIFIČNA ZA TGF-ß1 | |
| JP2013139478A (ja) | インターフェロンβおよびＩＬ−２Ｒアンタゴニストを用いて自己免疫疾患を治療する方法 | |
| AU2005291741B2 (en) | Type I interferon blocking agents for prevention and treatment of psoriasis | |
| EP2425250B1 (en) | Methods for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients | |
| CN101466735A (zh) | 多发性硬化和/或类风湿性关节炎的治疗 | |
| Hohlfeldf | Therapeutic strategies in multiple sclerosis. I. Immunotherapy | |
| KR20210042138A (ko) | 건선 치료 방법 | |
| Bahner et al. | Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients | |
| CA2771335A1 (en) | Use of an immunoregulatory nk cell population for monitoring the efficacy of anti-il-2r antibodies in multiple sclerosis patients | |
| JP2019519470A5 (https=) | ||
| AU2014200946A1 (en) | Combination therapy for treatment of immune disorders | |
| PL448731A1 (pl) | Przeciwciała bispecyficzne anty–IL-17A i anty-IL-6 oraz ich zastosowanie w terapii, zwłaszcza w leczeniu chorób immunologicznych | |
| HK1051965A1 (en) | Use of il-18 inhibitors | |
| HK1051965B (en) | Use of il-18 inhibitors |